Your browser is no longer supported. Please, upgrade your browser.
ENOB Enochian Biosciences Inc. daily Stock Chart
Enochian Biosciences Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own0.10% Shs Outstand41.95M Perf Week-13.98%
Market Cap216.88M Forward P/E- EPS next Y- Insider Trans- Shs Float13.82M Perf Month-9.30%
Income-29.90M PEG- EPS next Q- Inst Own2.40% Short Float2.83% Perf Quarter-27.89%
Sales- P/S- EPS this Y-138.80% Inst Trans- Short Ratio10.32 Perf Half Y-19.22%
Book/sh3.88 P/B1.33 EPS next Y- ROA-17.10% Target Price- Perf Year-1.52%
Cash/sh0.25 P/C21.06 EPS next 5Y- ROE-19.90% 52W Range3.32 - 9.50 Perf YTD-26.14%
Dividend- P/FCF- EPS past 5Y-8.80% ROI- 52W High-47.16% Beta0.34
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low51.20% ATR0.52
Employees2 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)32.91 Volatility11.39% 9.19%
OptionableNo Debt/Eq0.00 EPS Q/Q-6.30% Profit Margin- Rel Volume0.69 Prev Close5.17
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume37.87K Price5.02
Recom- SMA20-18.01% SMA50-18.94% SMA200-23.86% Volume10,660 Change-2.90%
Jun-03-19 07:00AM  Enochian BioSciences Inventor Named to Two Important Scientific Committees GlobeNewswire
Apr-29-19 09:19AM  Enochian Biosciences (NASDAQ:ENOB) Shareholders Have Enjoyed A 37% Share Price Gain Simply Wall St. -8.15%
Mar-07-19 12:45PM  Successful Treatment of London Patient Underscores Clinical Potential of Enochian Biosciences Gene Modified Cellular Therapy for HIV GlobeNewswire -6.88%
Feb-01-19 02:31PM  4 Healthcare Stocks Looking To Start February Off Strong ACCESSWIRE +9.88%
Jan-16-19 04:00PM  OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire +10.00%
Jan-07-19 08:30AM  Enochian Biosciences Announces Appointment of Dr. Mark Dybul as Executive Vice-Chair GlobeNewswire
Jan-04-19 08:00AM  How Much Of Enochian Biosciences Inc. (NASDAQ:ENOB) Do Insiders Own? Simply Wall St.
Dec-05-18 08:30AM  Enochian Biosciences Announces Uplisting to Nasdaq Under Symbol ENOB GlobeNewswire
Dec-03-18 08:30AM  Enochian Biosciences to Present at Biotech Showcase 2019 GlobeNewswire
Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.